ARX 0.91% 54.5¢ aroa biosurgery limited

Ann: New Study Shows Myriad Efficacy in Exposed Vital Structures, page-2

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 93 Posts.
    lightbulb Created with Sketch. 11
    The study showed 100% healing when Myriad™ was used in six surgical reconstructions of soft tissue defects with exposed vital structures and included a variety of different wound types; e.g. full thickness scalp excision, scar revision surgery, tumor (squamous cell carcinoma) excision, traumatic wound, surgical dehiscence, and fistula.

    “Some of the procedures where Myriad™ performed well are very high-volume procedures. For example, the American Society of Plastic Surgeonsi estimates there are 4.4 million tumor resections per annum and around 180,000 scar revision procedures each year in the US, so it is very positive to see this proven efficacy and absence of complications,”
 
watchlist Created with Sketch. Add ARX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.